首页> 外文期刊>Nuclear Medicine Review >Use of Tc99m-nanocolloid for sentinel nodes identification in cervical cancer
【24h】

Use of Tc99m-nanocolloid for sentinel nodes identification in cervical cancer

机译:Tc99m-纳米胶体在宫颈癌前哨淋巴结鉴别中的应用

获取原文
获取外文期刊封面目录资料

摘要

BACKGROUND: The initial draining lymph node for a primary tumor is referred to as the “sentinel” node. Firstly adopted in the management of patients with cutaneous melanoma and breast cancer, it is now widely tested in cervical cancer. In patients with cervical cancer, lymph node status is the most important prognostic factor for survival. In patients with cervical cancer FIGO stage I and II pelvic lymph node metastases are expected in 0–16 and 24.5-31% and para-aortic lymph node metastases are expected in 0–22 and 11–19% of patients. The removal of pelvic and para-aortic lymph nodes is essential for assessing the biology of the disease. Lymphoscintigraphy enables the visualisation of lymphatic drainage patterns from a great variety of tumour sites prior to surgery. Therefore, the current procedure is to perform the pre-operative mapping of sentinel nodes by static and/or dynamic lymphoscintigraphy, followed by in vivo identification using a gamma detection probe and selective surgical resection. MATERIAL AND METHODS: Between 2001–2003, 37 patients with cervical cancer FIGO stage I-IIa were seemed to be qualified to undergo lymphoscintigraphy. The day before surgery 99m Tc-nanocolloid (100 MBq; 0.5–1.0 ml in volume) was applied in each quadrant of the cervix or around the tumor. The static scintigraphic scans were performed after 2 hours p.i. using a dual-head large-field-of-view Siemens gamma-camera equipped with high resolution collimators. SNs were identified intra-operatively using a handheld gamma detection probe (Navigator GPS-Tyco) and intra-operative lymphatic mapping with blue dye. After a resection of the SNs, a standard radical hysterectomy with pelvic and low para-aortic lymph node dissection was performed. Tumor characteristics were compared with sentinel node detection and with the histopathological and immunohistochemical results. RESULTS: The scintigraphy showed a focal uptake in 35 of the 37 patients. In all women one or more sentinel lymph nodes were identified intra-operatively. Of them, 24 patients had those located bilaterally. Histologically positive SNs were found in 5 women (13.5%). CONCLUSIONS: A combination pre-operatively administered radioactively labelled albumin with blue dye allows the successful detection of SN in patient with cervical cancer. This technique will result in a real advance in the less aggressive management of patients with early stage cervical cancer. Sentinel lymph node status may be representative of the pelvic lymph nodes status in cervical cancer and thus could provide important information for further treatment.
机译:背景:原发性肿瘤最初的引流淋巴结被称为“前哨”淋巴结。最初用于皮肤黑色素瘤和乳腺癌患者的治疗,现已在宫颈癌中得到广泛测试。在子宫颈癌患者中,淋巴结状态是生存的最重要预后因素。在患有宫颈癌的患者中,FIGO的I和II期骨盆淋巴结转移预计在0–16和24.5–31%,主动脉旁淋巴结转移预计在0–22和11–19%的患者中。盆腔和主动脉旁淋巴结的清除对于评估疾病的生物学至关重要。淋巴造影可以在手术前可视化各种肿瘤部位的淋巴引流模式。因此,当前的程序是通过静态和/或动态淋巴显像术对前哨淋巴结进行术前定位,然后使用伽马探测探针和选择性手术切除术进行体内鉴定。材料与方法:在2001年至2003年之间,有37例FIGO I-IIa期宫颈癌患者符合接受淋巴造影的资格。手术前一天,在子宫颈的每个象限或肿瘤周围应用99m Tc-纳米胶体(100 MBq;体积为0.5-1.0 ml)。静息闪烁扫描在p.i 2小时后进行。使用配备高分辨率准直仪的双头大视野西门子伽玛相机。使用手持式伽玛检测探针(Navigator GPS-Tyco)在术中鉴定SN,并在术中用蓝色染料标出淋巴图。切除SN后,进行标准的根治性子宫切除术,包括盆腔和低主动脉旁淋巴结清扫术。将肿瘤特征与前哨淋巴结检测以及组织病理学和免疫组织化学结果进行比较。结果:闪烁显像显示37例患者中有35例局部吸收。在所有女性中,术中发现一个或多个前哨淋巴结。其中24例患者位于两侧。在5名妇女中发现了组织学阳性的SN(13.5%)。结论:术前将放射性标记的白蛋白与蓝色染料联合使用可成功检测宫颈癌患者的SN。该技术将在早期宫颈癌患者的积极性降低方面取得真正的进步。前哨淋巴结状况可能代表宫颈癌的盆腔淋巴结状况,因此可为进一步治疗提供重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号